Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ustekinumab biosimilar - Bio-Thera Solutions

Next Previous
Drug Profile

Ustekinumab biosimilar - Bio-Thera Solutions

Alternative Names: BAT-2206; STARJEMZA; ustekinumab-hmny

Latest Information Update: 25 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bio-Thera Solutions
  • Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Antiulcers; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin 12 inhibitors; Interleukin 23 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Autoimmune disorders

Highest Development Phases

  • Registered Crohn's disease; Plaque psoriasis; Psoriatic arthritis; Ulcerative colitis
  • No development reported Autoimmune disorders

Most Recent Events

  • 20 Jun 2025 Bio-Thera Solutions receives positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency recommends approval of ustekinumab biosimilar for Plaque psoriasis
  • 27 May 2025 Registered for Crohn's disease in USA (IV)
  • 27 May 2025 Registered for Crohn's disease in USA (SC)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top